{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:25:23Z","timestamp":1786980323776,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00535-025-02279-z","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T10:06:09Z","timestamp":1751969169000},"page":"1259-1271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis: a multicenter I\u2011BRITE cohort study"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-7638","authenticated-orcid":false,"given":"Shintaro","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Shiroyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kamoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kashimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuho","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ariga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kashimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichiro","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2279_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Prim. 2020;6:74.","journal-title":"Nat Rev Dis Prim"},{"key":"2279_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.14309\/ajg.0000000000003143","volume":"120","author":"P Danpanichkul","year":"2024","unstructured":"Danpanichkul P, Duangsonk K, Ho AHY, et al. Disproportionately increasing incidence of inflammatory bowel disease in female patients and the elderly: an update analysis from the global burden of disease study 2021. Am J Gastroenterol. 2024;120:675\u201380.","journal-title":"Am J Gastroenterol"},{"key":"2279_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00535-019-01580-y","volume":"54","author":"M Higashiyama","year":"2019","unstructured":"Higashiyama M, Sugita A, Koganei K, et al. Management of elderly ulcerative colitis in Japan. J Gastroenterol. 2019;54:571\u201386.","journal-title":"J Gastroenterol"},{"key":"2279_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/ecco-jcc\/jjaa181","volume":"15","author":"JWY Mak","year":"2021","unstructured":"Mak JWY, Lok Tung Ho C, Wong K, et al. Epidemiology and natural history of elderly-onset inflammatory bowel disease: results from a territory-wide Hong Kong IBD registry. J Crohns Colitis. 2021;15:401\u20138.","journal-title":"J Crohns Colitis"},{"key":"2279_CR5","doi-asserted-by":"publisher","unstructured":"Kobayashi T, Hisamatsu T, Motoya S, et al. Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study. Intest Res 2025. https:\/\/doi.org\/10.5217\/ir.2024.00063","DOI":"10.5217\/ir.2024.00063"},{"key":"2279_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/apt.18406","volume":"61","author":"S Akiyama","year":"2025","unstructured":"Akiyama S, Shimizu H, Tamura A, et al. Comparative efficacy and safety of three janus kinase inhibitors in ulcerative colitis: a real-world multicentre study in Japan. Aliment Pharmacol Ther. 2025;61:524\u201337.","journal-title":"Aliment Pharmacol Ther"},{"key":"2279_CR7","first-page":"024","volume":"6","author":"K Ando","year":"2024","unstructured":"Ando K, Fujiya M, Ueno N, et al. Effectiveness and persistency of ustekinumab treatment for ulcerative colitis: a phoenix retrospective cohort study. Crohns Colitis. 2024;6:024.","journal-title":"Crohns Colitis"},{"key":"2279_CR8","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/apt.70140","volume":"61","author":"Y Takagi","year":"2025","unstructured":"Takagi Y, Sato T, Nishiguchi T, et al. Real-world effectiveness and safety of mirikizumab induction therapy in patients with ulcerative colitis: a multicentre retrospective observational study. Aliment Pharmacol Ther. 2025;61:1923\u201334.","journal-title":"Aliment Pharmacol Ther"},{"key":"2279_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/jgh.15138","volume":"36","author":"S Hiraoka","year":"2021","unstructured":"Hiraoka S, Fujiwara A, Toyokawa T, et al. Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. J Gastroenterol Hepatol. 2021;36:137\u201343.","journal-title":"J Gastroenterol Hepatol"},{"key":"2279_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5217\/ir.2019.00084","volume":"18","author":"S Mizuno","year":"2020","unstructured":"Mizuno S, Ono K, Mikami Y, et al. 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis. Intest Res. 2020;18:69\u201378.","journal-title":"Intest Res"},{"key":"2279_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/apt.16120","volume":"53","author":"S Hibiya","year":"2021","unstructured":"Hibiya S, Matsuyama Y, Fujii T, et al. 5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2021;53:103\u201313.","journal-title":"Aliment Pharmacol Ther"},{"key":"2279_CR12","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00535-018-1486-7","volume":"53","author":"Y Kakuta","year":"2018","unstructured":"Kakuta Y, Kawai Y, Okamoto D, et al. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018;53:1065\u201378.","journal-title":"J Gastroenterol"},{"key":"2279_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00535-024-02099-7","volume":"59","author":"M Makuuchi","year":"2024","unstructured":"Makuuchi M, Kakuta Y, Umeno J, et al. Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study. J Gastroenterol. 2024;59:468\u201382.","journal-title":"J Gastroenterol"},{"key":"2279_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00535-017-1416-0","volume":"53","author":"Y Kakuta","year":"2018","unstructured":"Kakuta Y, Kinouchi Y, Shimosegawa T. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping. J Gastroenterol. 2018;53:172\u201380.","journal-title":"J Gastroenterol"},{"key":"2279_CR15","unstructured":"Ministry of Health, Labour and Welfare of Japan. Number of Physicians per 100,000 Population by Prefecture. https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/ishi\/06\/tou13.html Accessed 25 Mar 2025."},{"key":"2279_CR16","unstructured":"Ministry of Health, Labour and Welfare of Japan. Special Functioning Hospitals. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000137801.html Accessed 25 Mar 2025."},{"key":"2279_CR17","unstructured":"University of Tsukuba Hospital. Medical Center for Intractable Diseases. https:\/\/www.hosp.tsukuba.ac.jp\/outpatient\/facility\/nanbyou\/ Accessed 27 Mar 2015."},{"key":"2279_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","volume":"17","author":"H Gordon","year":"2023","unstructured":"Gordon H, Biancone L, Fiorino G, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis. 2023;17:827\u201354.","journal-title":"J Crohns Colitis"},{"key":"2279_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/MCG.0000000000001860","volume":"58","author":"DS Dahiya","year":"2024","unstructured":"Dahiya DS, Chandan S, Bapaye J, et al. Safety and effectiveness of vedolizumab in elderly patients with inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2024;58:378\u201388.","journal-title":"J Clin Gastroenterol"},{"key":"2279_CR20","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1053\/j.gastro.2010.04.001","volume":"138","author":"N Chalasani","year":"2010","unstructured":"Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138:2246\u201359.","journal-title":"Gastroenterology"},{"key":"2279_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489\u2013526.","journal-title":"J Gastroenterol"},{"key":"2279_CR22","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.3748\/wjg.v23.i35.6385","volume":"23","author":"A Vasudevan","year":"2017","unstructured":"Vasudevan A, Gibson PR, van Langenberg DR. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told? World J Gastroenterol. 2017;23:6385\u2013402.","journal-title":"World J Gastroenterol"},{"key":"2279_CR23","doi-asserted-by":"publisher","first-page":"175628482110364","DOI":"10.1177\/17562848211036456","volume":"14","author":"H Cichoz-Lach","year":"2021","unstructured":"Cichoz-Lach H, Michalak A, Kopertowska-Majchrzak M, et al. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therap Adv Gastroenterol. 2021;14:17562848211036456.","journal-title":"Therap Adv Gastroenterol"},{"key":"2279_CR24","unstructured":"Ministry of Internal Affairs and Communications of Japan. Elderly in our country from a statistical perspective\u2014in commemoration of \u2018respect for the aged day\u2019. https:\/\/www.stat.go.jp\/data\/topics\/topi1380.html 17 Sept 2023."},{"key":"2279_CR25","unstructured":"National Cancer Center Japan. Latest Cancer Statistics. https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html 16 Dec 2024."},{"key":"2279_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/14740338.2017.1300251","volume":"16","author":"G Novak","year":"2017","unstructured":"Novak G, Hindryckx P, Khanna R, et al. The safety of vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017;16:501\u20137.","journal-title":"Expert Opin Drug Saf"},{"key":"2279_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41391-019-0177-7","volume":"23","author":"Y Ge","year":"2020","unstructured":"Ge Y, Shi Q, Yao W, et al. The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis. 2020;23:53\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2279_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12916-023-03096-y","volume":"21","author":"H Gao","year":"2023","unstructured":"Gao H, Zheng S, Yuan X, et al. Causal association between inflammatory bowel disease and 32 site-specific extracolonic cancers: a Mendelian randomization study. BMC Med. 2023;21:389.","journal-title":"BMC Med"},{"key":"2279_CR29","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/ecco-jcc\/jjaa036","volume":"14","author":"FH Mourad","year":"2020","unstructured":"Mourad FH, Hashash JG, Kariyawasam VC, et al. Ulcerative colitis and cytomegalovirus infection: from A to Z. J Crohns Colitis. 2020;14:1162\u201371.","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02279-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02279-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02279-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:33:49Z","timestamp":1774582429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02279-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2279"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02279-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.A. has received lecture fees from Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited, Janssen Pharmaceutical K.K., Pfizer Japan Inc., Gilead Sciences K.K., EA Pharma Co., Ltd., AbbVie GK, Mochida Pharmaceutical Co., Ltd., Viatris Pharmaceuticals Japan Inc., JIMRO Co., Ltd., Celltrion Healthcare Japan Co., Ltd., KISSEI Pharmaceutical Co., Ltd., Sandoz K.K., Kyorin Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Olympus Corporation, Nippon Kayaku Co., Ltd., Bristol-Myers Squibb Company, and Zeria Pharmaceutical Co., Ltd., writing fees from Jiho Inc., Ishiyaku Publishers, Inc., Nankodo Co., Ltd., and Nippon Rinsho Co., Ltd., and research grants from Mochida Pharmaceutical Co., Ltd. Y.I. has received lecture fees from EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Kyorin Pharmaceutical Co., Ltd. M.O. has received lecture fees from Kyorin Pharmaceutical Co., Ltd., AbbVie GK, Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., EA Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Mochida Pharmaceutical Co., Ltd., KISSEI Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Bayer Yakuhin, Ltd., and Eli Lilly Japan. T.K. (Hitachi General Hospital) has received lecture fees from AbbVie GK, Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., KISSEI Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K. H.K. has received lecture fees from Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited, Janssen Pharmaceutical K.K., and Mochida Pharmaceutical Co., Ltd. J.I. has received lecture fees from Mochida Pharmaceutical Co., Ltd. K.I. (Tsukuba Memorial Hospital) has received lecture fee from Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Viatris Pharmaceuticals Japan Inc., AbbVie GK, and KISSEI Pharmaceutical Co., Ltd. Y.H. has received lecture fees from AbbVie GK, Astellas Pharma Inc., AstraZeneca K.K., Asahi Kasei Pharma Corporation, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Esai Co., Ltd., Eli Lilly Japan K.K., KISSEI Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Taiho Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Olympus Marketing, Inc., Merk Biopharma Co., Ltd., Kowa Company, Ltd., and Daiichi Sankyo Co., Ltd. J.H. has received lecture fees from AbbVie GK and Mochida Pharmaceutical Co., Ltd. T.M. has received lecture fees from AbbVie GK, Olympus Corporation, Viatris Pharmaceuticals Japan Inc., Mochida Pharmaceutical Co., Ltd., Nipro ES Pharma Co., Ltd., Bristol-Myers Squibb Company, and Otsuka Pharmaceutical Co., Ltd., and supports for attending meetings from AbbVie GK. S.F. has received lecture fees from Takeda Pharmaceutical Company Limited and Mochida Pharmaceutical Co., Ltd. H.A. has received lecture fees from AbbVie GK, Mochida Pharmaceutical Co., Ltd., Eisai Co., Ltd., KISSEI Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceutical Company Limited. J.K. has received lecture fees from AbbVie GK. M.N. (Kasumigaura Medical Center) has received lecture fees from KISSEI Pharmaceutical Co., Ltd. K.T. has received lecture fees from EA Pharma Co., Ltd., AbbVie GK, Janssen Pharmaceutical K.K., KISSEI Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, and Viatris Pharmaceuticals Japan Inc., and research grants from Eli Lilly. K.T. serves in leadership roles in the Japanese Society of Inflammatory Bowel Disease without receiving any financial compensation. M.S., S.S., R.S., T.K. (Tsukuba Central Hospital), K.I. (Koyama Memorial Hospital), and M.N. (Tsukuba Medical Center Hospital) have no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethics committees and institutional review boards of all 13 participating hospitals approved the conduct of this study with the opt-out method.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"As this study involved a retrospectively analysis of existing data, waiver of informed consent for this study was approved. All efforts were made to ensure confidentiality of the data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}